Eli Lilly and (LLY) earnings
In the quarter ended June 2026, Eli Lilly and had revenue of $23.0B, up 47.7% on a year earlier, and diluted EPS of 7.94.
On August 5, 2026 it reported EPS of 8.38 against an estimate of 6.01 (beat).
The next report is expected on Thursday, October 29, 2026 before the market opens, with EPS expected around 9.83.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Thu Oct 29, 2026 | Before open | 9.83 | — |
| Last | Wed Aug 5, 2026 | Before open | 6.01 | 8.38 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Eli Lilly and's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $23.0B | +47.7% | 7.94 | +26.2% | — | 2026-08-05 |
| Mar 31, 2026 | $19.8B | +55.5% | 8.26 | +169.9% | — | 2026-04-30 |
| Dec 31, 2025 | $19.3B | +42.6% | — | — | — | 2026-02-12 |
| Sep 30, 2025 | $17.6B | +53.9% | 6.21 | +480.4% | — | 2025-10-30 |
| Jun 30, 2025 | $15.6B | +37.6% | 6.29 | +91.8% | — | 2025-08-07 |
| Mar 31, 2025 | $12.7B | +45.2% | 3.06 | +23.4% | — | 2025-05-01 |
| Dec 31, 2024 | $13.5B | +44.7% | — | — | — | 2025-02-19 |
| Sep 30, 2024 | $11.4B | +20.4% | 1.07 | — | — | 2024-10-30 |
| Jun 30, 2024 | $11.3B | +36.0% | 3.28 | +68.2% | — | 2024-08-08 |
| Mar 31, 2024 | $8.8B | +26.0% | 2.48 | +66.4% | — | 2024-04-30 |
| Dec 31, 2023 | $9.4B | +28.1% | — | — | — | 2024-02-21 |
| Sep 30, 2023 | $9.5B | +36.8% | -0.06 | -103.7% | — | 2023-11-02 |
Questions
When does Eli Lilly and report earnings?
Eli Lilly and's next earnings report is expected on October 29, 2026 before the market opens.
How did Eli Lilly and do last quarter?
In the quarter ended June 2026, Eli Lilly and had revenue of $23.0B, up 47.7% on a year earlier, and diluted EPS of 7.94.
From Eli Lilly and's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.